Core Viewpoint - The stock of Furuida has experienced fluctuations, with a recent decline in price and significant net outflow of funds, indicating potential investor concerns about the company's performance and market position [1][2]. Financial Performance - Furuida's stock price has increased by 3.33% year-to-date, but has seen declines of 3.37% over the last five trading days, 9.57% over the last 20 days, and 6.17% over the last 60 days [2]. - For the first half of 2025, Furuida reported revenue of 1.79 billion yuan, a year-on-year decrease of 7.05%, and a net profit attributable to shareholders of 108 million yuan, down 15.16% year-on-year [2]. Shareholder Information - As of June 30, 2025, Furuida had 47,500 shareholders, an increase of 8.26% from the previous period, with an average of 21,396 circulating shares per shareholder, a decrease of 7.63% [2]. - The company has distributed a total of 1.196 billion yuan in dividends since its A-share listing, with 213 million yuan distributed over the last three years [3]. Market Activity - Furuida has appeared on the "Dragon and Tiger List" once this year, with the most recent appearance on June 11, where it recorded a net buy of -9.7777 million yuan [2]. - The company's main business segments include cosmetics (61.13%), property management and others (16.37%), pharmaceuticals (11.57%), and raw materials and derivatives (9.98%) [2]. Institutional Holdings - As of June 30, 2025, Hong Kong Central Clearing Limited was the ninth largest circulating shareholder, holding 4.8242 million shares, a decrease of 1.4592 million shares from the previous period [3]. - The Southern CSI 1000 ETF (512100) entered as the tenth largest circulating shareholder, holding 472,070 shares [3].

Market Overview - On September 16, the cosmetics sector rose by 0.03% compared to the previous trading day, with Shuiyang Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 3861.87, up 0.04%, while the Shenzhen Component Index closed at 13063.97, up 0.45% [1] Individual Stock Performance - Shuiyang Co., Ltd. (300740) closed at 22.48, with a gain of 1.63% and a trading volume of 208,500 shares, amounting to a transaction value of 469 million yuan [1] - Qingdao Kingway (002094) closed at 8.47, up 1.44%, with a trading volume of 326,600 shares and a transaction value of 277 million yuan [1] - Other notable performers include: - Kezhou Co., Ltd. (300856) at 14.23, up 0.57% [1] - Beitaini (300957) at 49.13, up 0.41% [1] - Furuida (600223) at 7.91, up 0.38% [1] Fund Flow Analysis - The cosmetics sector experienced a net outflow of 43.2 million yuan from institutional investors, while retail investors saw a net outflow of 23.0 million yuan [2] - Conversely, speculative funds recorded a net inflow of 66.2 million yuan [2] Detailed Fund Flow for Key Stocks - Shuiyang Co., Ltd. (300740) had a net inflow of 41.1 million yuan from institutional investors, while retail investors faced a net outflow of 71.8 million yuan [3] - Qingdao Kingway (002094) saw a net inflow of 15.3 million yuan from institutional investors, but a net outflow of 7.2 million yuan from retail investors [3] - Other stocks with significant fund flow include: - Beitaini (300957) with a net inflow of 5.7 million yuan from institutional investors and a net outflow of 13.2 million yuan from retail investors [3] - Furuida (600223) faced a net outflow of 10.2 million yuan from institutional investors but a net inflow of 8.9 million yuan from retail investors [3]

Market Overview - On September 15, the cosmetics sector declined by 0.18%, with Huaye Fragrance leading the drop [1] - The Shanghai Composite Index closed at 3860.5, down 0.26%, while the Shenzhen Component Index closed at 13005.77, up 0.63% [1] Individual Stock Performance - Notable gainers included: - Jinsong New Material (300849) with a closing price of 14.48, up 3.72% and a trading volume of 121,800 shares, totaling 179 million yuan [1] - Lafang Home (603630) closed at 28.58, up 2.11% with a trading volume of 71,300 shares, totaling 200 million yuan [1] - Notable decliners included: - Huaye Fragrance (300886) closed at 29.66, down 1.79% with a trading volume of 18,400 shares, totaling 55.05 million yuan [2] - Marubi Biological (603983) closed at 39.95, down 1.36% with a trading volume of 13,900 shares, totaling 55.49 million yuan [2] Capital Flow Analysis - The cosmetics sector experienced a net outflow of 83.38 million yuan from institutional investors, while retail investors saw a net inflow of 76.42 million yuan [2] - The overall capital flow for individual stocks showed: - Jinsong New Material had a net inflow of 18.50 million yuan from institutional investors, accounting for 10.31% of its total [3] - Huaye Fragrance had a net outflow of 4.23 million yuan from institutional investors, accounting for 6.58% of its total [3]

Investment Rating - The report initiates coverage with a "Buy" rating for Shuiyang Co., Ltd. [3][13] Core Insights - The cosmetics and medical beauty sector underperformed the market, with the Shenwan Beauty Care Index increasing by 0.2% from September 5 to September 12, 2025, lagging behind the Shenwan A Index by 2.7 percentage points [3][4] - Domestic cosmetics brands showed strong growth in August, with key brands under Shumei Co. achieving a 70% growth rate on Douyin and Taobao platforms, indicating a robust performance despite high base effects [3][9] - The report highlights the upcoming Double 11 shopping festival, suggesting that brands should prepare for promotional strategies [3][9] Summary by Sections Industry Performance - The cosmetics and medical beauty sector's performance was weaker than the market, with declines in the Shenwan Cosmetics Index by 0.5% and the Shenwan Personal Care Index by 0.8% during the specified period [3][4] Key Company Review - Shuiyang Co., Ltd. is positioned as a leading technology-driven beauty company in China, with stable revenue between 4 to 5 billion yuan from 2021 to 2024 and an expected gross margin of 63.01% in 2024, up by 10.94 percentage points from 2021 [3][10] - The company has a dual business model of proprietary brands and CP agency brands, with a strong focus on high-end and global market transformation [3][10][12] E-commerce Data - In August, key domestic brands on Douyin and Taobao platforms showed significant growth, with Shumei Co. brands achieving a 70% increase, and other brands like Maogeping and Runben also reporting substantial growth rates [3][14] Market Trends - The report notes that the overall retail sales of cosmetics in July 2025 grew by 4.5%, indicating a recovery in consumer spending [3][17] - The domestic skincare market is projected to reach 271.2 billion yuan in 2024, despite a slight decline of 3.7% year-on-year, with domestic brands gaining market share [3][26] Company Announcements - Shumei Co. has appointed Dr. Karl Lintner, a pioneer in peptide beauty, as the chief scientific advisor, aiming to enhance its global competitiveness in research and development [3][21]

Investment Rating - The investment rating for the company is "Buy" and is maintained [7] Core Views - The company reported a revenue of 1.79 billion yuan for H1 2025, a year-on-year decline of 7.05%, and a net profit attributable to shareholders of 110 million yuan, down 15.2% year-on-year [2][4] - In Q2 alone, the company achieved a revenue of 910 million yuan, a decrease of 11.7% year-on-year, with a net profit of 57.25 million yuan, down 16.1% year-on-year [2][4] - The cosmetics business, particularly the Yilian brand, showed steady growth, while the Aier Doctor brand is undergoing a phase of adjustment [10] Summary by Sections Financial Performance - For H1 2025, the cosmetics, pharmaceutical, and raw materials segments generated revenues of 1.09 billion, 210 million, and 180 million yuan respectively, with year-on-year changes of -7.7%, -13.9%, and +4.2% [10] - The Yilian brand achieved a revenue of 550 million yuan, a growth of 23.8% year-on-year, while the Aier Doctor brand saw a revenue decline of 30% to 450 million yuan [10] - The overall gross profit margin slightly improved, with a net profit margin of 6%, down 0.6 percentage points year-on-year [10] Business Segments - The Yilian brand's growth was supported by the announcement of a global spokesperson, leading to a 43% increase in the spray product line [10] - The Aier Doctor brand is in a brand adjustment phase, with new product launches expected to drive future growth [10] - The raw materials business showed stability, with sales of hyaluronic acid reaching 120 million yuan, a year-on-year increase of 23.4% [10] Future Outlook - The company is expected to focus on its main brands, with the Yilian brand showing strong momentum and the Aier Doctor brand undergoing necessary adjustments [10] - The company anticipates improvements in profitability due to optimized channel structures and enhanced gross margins in the raw materials segment [10] - EPS forecasts for 2025-2027 are projected at 0.24, 0.29, and 0.34 yuan per share respectively [10]

Group 1 - The company received a warning letter from the Zhejiang Securities Regulatory Bureau due to issues related to the improper use of raised funds, failure to disclose related party transactions in a timely manner, and inaccuracies in periodic reports [1] - The company is committed to addressing the issues highlighted in the warning letter by enhancing internal compliance and improving the quality of information disclosure to protect shareholder interests [1] Group 2 - The company specializes in the research, production, and sales of cosmetic plastic packaging containers, with key products including cream jars and lotion bottles [2] - The company's IPO fundraising projects included a technical transformation project to increase production capacity by 15 million sets of cosmetic packaging containers and a new project to produce 45 million sets, utilizing funds of 92.22 million yuan and 200.63 million yuan respectively [2] - The company has fully utilized its IPO funds by the end of 2023, and all fundraising accounts have been closed [2] Group 3 - The company has established stable and long-term relationships with well-known cosmetic brands such as Estée Lauder and Shanghai Jahwa, leveraging its product quality and management capabilities to attract high-end clients [3] - The global cosmetic packaging market is projected to grow from 30.055 billion USD in 2024 to 36.206 billion USD by 2028, indicating strong growth potential driven by demand for personalized and high-end designs [3] - The rise of domestic brands through social e-commerce platforms like Douyin presents structural growth opportunities for domestic cosmetic packaging companies, which may further expand the company's development space as its fundraising projects come online [3]

Core Viewpoint - The recent regulatory movement in the pharmaceutical sector, particularly the classification of exosomes as advanced therapy medicinal products (ATMP), has significant implications for the beauty industry, especially in the development of skincare products utilizing exosomes [3][5][31]. Regulatory Developments - In July 2023, the National Medical Products Administration (NMPA) released guidelines that clarify the classification of cell therapy products, officially categorizing exosomes as drugs [3][5]. - This regulatory clarity resolves previous ambiguities regarding the status of stem cells and exosomes, which are now recognized as pharmaceutical products [5][31]. Industry Trends - Over 17 beauty-related companies, including major players like L'Oréal and Estée Lauder, are actively exploring the potential of exosomes in skincare, indicating a growing trend towards innovative beauty solutions [5][17]. - Exosomes are gaining attention for their unique properties, such as promoting skin rejuvenation and anti-aging effects, which are increasingly being recognized in the beauty industry [9][13]. Scientific Background - Exosomes are small vesicles secreted by cells, containing proteins and nucleic acids, and are involved in intercellular communication [7][8]. - The scientific foundation for exosome research has been bolstered by Nobel Prize-winning discoveries related to cell communication and gene regulation [8][9]. Market Potential - The market for exosome-related skincare products is expanding, with significant sales growth observed on platforms like Douyin, where sales reached 1.646 billion yuan in the first half of 2025, marking a year-on-year increase of 359.8% [25][27]. - The average price of exosome-related skincare products on Douyin was 371.46 yuan, indicating a premium positioning in the market [25]. Challenges Ahead - Despite the promising potential, the beauty industry faces challenges related to regulatory compliance, as current regulations in China do not recognize exosomes as valid cosmetic ingredients [29][30]. - There is also a need for clearer technical standards and clinical evidence to support the efficacy and safety of exosome-based products [32][33].

Core Viewpoint - The skincare and daily chemical industry in A-share listed companies has shown significant performance divergence in the first half of 2025, with 14 representative companies analyzed for their financial results [1]. Group 1: Performance Analysis - Six companies experienced declines in both revenue and net profit: Lafang Jiahua, Furuida, Fulejia, Beitaini, Huaxi Biological, and Kesi Co. [1] - Lafang Jiahua reported revenue of 410 million yuan, a decrease of 4.27% year-on-year, and a net profit of 6 million yuan, down 82.89% compared to the previous year [1]. - Furuida achieved revenue of 1.79 billion yuan, a decline of 7.05% year-on-year, with a net profit of 108 million yuan [1]. - One company, Chuang'er Biological, saw revenue growth of 16.98% to 214 million yuan but a net profit decline of 55.99% to 13 million yuan [1]. - Jiaheng Jiahua reported revenue of 514 million yuan, an increase of 21.72% year-on-year, but a net loss of 32 million yuan, with losses widening compared to the previous year [1]. Group 2: Factors Influencing Performance - Jiaheng Jiahua's significant net loss is closely linked to its Huzhou base, with new business expansions impacting operational performance [2]. - Lafang Jiahua's dual decline in performance is attributed to changes in the domestic and international operating environment, compounded by intensified industry competition, despite increased market investment [2].

Core Viewpoint - The skincare and daily chemical industry in A-share listed companies has shown significant performance divergence in the first half of 2025, with 6 companies experiencing both revenue and profit declines, while 6 others reported growth in both metrics, 1 company saw revenue growth without profit increase, and 1 company reported a loss [1][2]. Performance Summary - Among the 14 selected listed companies, 6 companies reported both revenue and profit declines: - Lafang Cosmetics: Revenue of 410 million, down 4.27%, net profit of 6 million, down 82.89% [2] - Furuida: Revenue of 1.79 billion, down 7.05%, net profit of 108 million, down 15.16% [2] - Fulejia: Revenue of 863 million, down 8.15%, net profit of 230 million, down 32.54% [2] - Beitaini: Revenue of 2.372 billion, down 15.43%, net profit of 247 million, down 49.01% [2] - Huaxi Biological: Revenue of 2.261 billion, down 19.57%, net profit of 221 million, down 35.38% [2] - Kesi Co.: Revenue of 721 million, down 48.67%, net profit of 65 million, down 84.51% [2] - One company, Chuang'er Biological, reported revenue growth of 16.98% to 214 million but a net profit decline of 55.99% to 13 million [3][4]. - One company, Jiaheng Cosmetics, reported revenue of 514 million, up 21.72%, but a net loss of 32 million, with losses significantly widening [5][6]. The loss was attributed to increased operational costs and fixed expenses related to its Huzhou base [5]. Industry Challenges - Lafang Cosmetics faced significant pressure from changing domestic and international operating environments, leading to increased sales and financial expenses despite a revenue decline [6].

Core Insights - The skincare and daily chemical industry in A-share has shown significant performance divergence among 14 representative listed companies in the first half of 2025, with 6 companies experiencing both revenue and profit declines, 6 companies achieving double growth, 1 company increasing revenue but not profit, and 1 company reporting a loss [1][2]. Performance Summary - **Companies with Double Growth**: 6 companies achieved both revenue and profit growth, although specific names and figures are not provided in the documents. - **Companies with Double Decline**: - Lafang Cosmetics: Revenue of 410 million yuan, down 4.27%, net profit of 6 million yuan, down 82.89% [2]. - Furuida: Revenue of 1.79 billion yuan, down 7.05%, net profit of 108 million yuan, down 15.16% [2]. - Fulejia: Revenue of 863 million yuan, down 8.15%, net profit of 230 million yuan, down 32.54% [2]. - Beitaini: Revenue of 2.372 billion yuan, down 15.43%, net profit of 247 million yuan, down 49.01% [2]. - Huaxi Biological: Revenue of 2.261 billion yuan, down 19.57%, net profit of 221 million yuan, down 35.38% [2]. - Kesi Co.: Revenue of 721 million yuan, down 48.67%, net profit of 65 million yuan, down 84.51% [2]. - **Company with Increased Revenue but Decreased Profit**: Chuang'er Biological achieved revenue of 214 million yuan, up 16.98%, but net profit decreased to 13 million yuan, down 55.99% [3][4]. - **Company Reporting a Loss**: Jiaheng Cosmetics reported revenue of 514 million yuan, up 21.72%, but a net loss of 32 million yuan, with losses expanding significantly [5][6]. The loss is attributed to increased operational costs and fixed expenses related to its Huzhou base [5]. Industry Challenges - Lafang Cosmetics cited increased market pressures and intensified competition as reasons for its significant profit decline, despite higher sales and financial expenses [6].